MTB - Comunicações e Conferências
Permanent URI for this collection
Browse
Browsing MTB - Comunicações e Conferências by Author "Ferreira, AC"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
- Acroparestesias, Diarreia e Dor Abdominal Recorrente – a Importância do “Awareness” no Diagnóstico da Doença RaraPublication . Freitas, J; Ferreira, AC; Vieira, JP; Candeias, F; Brito, MJ; Ramos, M; Farela Neves, J; Oliveira, L; Antunes, D; Sequeira, SIntrodução: A doença de Anderson-Fabry é uma doença hereditária ligada ao cromossoma X causada pela deficiência da enzima lisossomal alfa-galactosidase com acumulação de globotriaosilceramida e comprometimento multissistémico progressivo. No sexo masculino, manifesta-se geralmente na infância e adolescência com acroparestesias, angioqueratomas e sintomas gastrointestinais, evoluindo na idade adulta precoce com complicações cardíacas, neurológicas e renais. Caso clínico: Jovem de 14 anos, sexo masculino, internado por infeção respiratória. Na história clínica constatou-se quadro com cinco anos de evolução de dor abdominal intermitente, diarreia crónica e episódios recorrentes de dor nas mãos e pés, tipo queimadura, agravados pela febre. O tio materno tinha um quadro clínico semelhante. Foi feita investigação reumatológica, gastrointestinal, auto-imune, neurológica e genética, mas foi o “awareness” diagnóstico para esta entidade que motivou o pedido da atividade enzimática da alfa-galactosidase A e confirmou o diagnóstico de doença de Anderson-Fabry. O estudo molecular do gene GLA revelou, em hemizigotia, a mutação c.195-1G>A. O estudo familiar confirmou a doença no tio materno e em mais um familiar do sexo masculino e três do sexo feminino Comentários: O diagnóstico da doença de Anderson-Fabry é frequentemente tardio devido à raridade da doença, inespecificidade das manifestações iniciais e ao vasto espectro de diagnósticos diferenciais. O diagnóstico precoce é importante pela intervenção na progressão da doença com terapêutica enzimática de substituição. O rastreio familiar é fundamental para a detecção de casos pré-sintomáticos e sintomáticos ainda não diagnosticados.
- Early Infantil Krabbe Disease with Unusual SurvivalPublication . Ferreira, AC; Sequeira, SIntroduction: Globoid cell leukodystrophy (Krabbe disease) is caused by a deficiency of the lysosomal galactocerebrosidase that results in progressive demyelination. The sole treatment is hematopoietic cell transplantation, which is only effective if performed before the onset of signs. In the absence of treatment, most children with early infantile Krabbe disease die within 2 years. Case Report: Female patient, first child of non-consanguineous parents, apparently normal till the fifth month of age when she presented with irritability, stiffness with clenched fists, developmental delay and feeding difficulties that progressed rapidly to failure to thrive, apathy, psychomotor regression, few spontaneous movements and spastic tetraparesis. Cerebral MRI showed extensive cerebral white matter abnormalities, relatively sparing the U-fibers, with a pattern of radiating stripes. Galactocerebrosidase activity in leukocytes and fibroblasts and molecular studies confirmed the diagnosis of Krabbe disease. After the rapid and regressive initial phase, she showed no further clinical progression of the disorder and although she did not grow she even showed regression of irritability and had a stable evolution and good visual contact until death over the age of 5 years. Comments: Our case shows that patients may have a stabilized form of disease and that a longer survival than described in the literature without transplant is possible in some patients.
- Effects of a Shortage of Imiglucerase on Three Patients with Type I Gaucher DiseasePublication . Ferreira, AC; Sequeira, SBackground: Children with Gaucher disease type I (GD1) are usually treated with enzyme replacement therapy (ERT) at a dose of 30-60U/Kg/2W. Recently, due to an acute shortage supply of imiglucerase, a reduced dose or a reduced infusion frequency was recommended. Objective: To evaluate the effects of a reduced infusion frequency of imiglucerase over 15 months of follow-up. Patients and Methods: Three patients (1M:2F) were treated with ERT since a median age of 7 years (range 5-12). Only one had bone crisis and Erlenmeyer deformations. Median duration of treatment before dose reduction was 3 years (range 1-8). ERT resulted in total regression of symptoms, normalization of hematological parameters and progressive improvement of chitotriosidase in all patients. In August 2009 infusion schedule was changed from a media 45U/Kg every two weeks to every four weeks. Results: All patients remained asymptomatic and with no major change on hematological parameters except for the patient with bone crisis who presented subnormal platelet count. All patients showed an upward trend in chitotriosidase values. Comments: Although a longer follow-up is needed, is probable that even children completely stabilized can probably not be kept on lower doses even though the reduction of frequency of the infusions represent a lower social burden.